Posttreatment Immune Parameters Predict Cancer Control and Pneumonitis in Stage I Non-Small-Cell Lung Cancer Patients Treated With Stereotactic Ablative Radiotherapy.

@article{Zheng2018PosttreatmentIP,
  title={Posttreatment Immune Parameters Predict Cancer Control and Pneumonitis in Stage I Non-Small-Cell Lung Cancer Patients Treated With Stereotactic Ablative Radiotherapy.},
  author={Ye Zheng and Anhui Shi and Weihu Wang and Huiming A. Yu and Rong Yu and Dongming Li and Bo Xu and Huimin Ma and Jing You and Daqing Zhao and Leilei Jiang and Jianhao Geng and Guangying Zhu},
  journal={Clinical lung cancer},
  year={2018},
  volume={19 4},
  pages={
          e399-e404
        }
}
PURPOSE Stereotactic ablative body radiotherapy (SABR) represents an exciting, tolerable, and highly effective form of radiotherapy. Ongoing investigations into the interactions between radiotherapy and the immune system have uncovered new mechanisms that can be exploited to improve efficacy. We determined whether baseline or posttreatment immune parameters could predict disease control and toxicity in stage I non-small-cell lung cancer (NSCLC) patients treated with SABR. PATIENTS AND METHODS… CONTINUE READING

Similar Papers

References

Publications referenced by this paper.
SHOWING 1-10 OF 36 REFERENCES

Molecular and cellular mechanisms of pulmonary fibrosis

  • Fibrogenesis & tissue repair
  • 2012
VIEW 7 EXCERPTS
HIGHLY INFLUENTIAL

The antifibrogenic potential of PPARgamma ligands in pulmonary fibrosis.

  • Journal of investigative medicine : the official publication of the American Federation for Clinical Research
  • 2008
VIEW 6 EXCERPTS
HIGHLY INFLUENTIAL